{
  "story_id": "f66ec9e39ef49538560d47a806daf32c",
  "desk": "drm3",
  "revision": 1,
  "published_at": "2026-11-18T14:02:52.000Z",
  "content_hash": "c4b83eaaf9ea9ab6206483419f28dd0e6f3529cc2ed752793605a0d2a144033f",
  "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs",
  "basis": {
    "headline": "Hims & Hers Launches Peptide Treatments Acknowledging Efficacy Uncertainty",
    "dek": "Hims & Hers launches unapproved peptide treatments while noting limited efficacy data.",
    "prose": "Hims & Hers chief medical officer Dr. Anant Vinjamoori stated that full clinical data on optimal use and efficacy of the offered peptides is not currently available. [^1]\n\nHims & Hers Health announced on Wednesday it will launch its Peptides+ platform offering five compounded peptide and longevity treatments manufactured in the United States. [^2] None of the specific compounded peptide products offered by Hims & Hers have received approval from the United States Food and Drug Administration. [^3] Morgan Stanley cut its target to $25 from $28 and kept an Equal-Weight rating. [^4]\n\nNeedham lowered its target to $32 from $42 while staying Buy. [^5] Over 10,000 people signed up for Hims & Hers peptide treatment early access waitlist within 15 days of its launch in late October, per a company spokesperson. [^6] Jefferies cut its target to $24 from $31 and kept Hold. [^7]\n\nThe stock is below its short-, medium-, and long-term moving averages. [^8]",
    "cited": "[{\"statement\":\"Hims & Hers chief medical officer Dr. Anant Vinjamoori stated that full clinical data on optimal use and efficacy of the offered peptides is not currently available.\",\"source\":\"CNBC\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-18T14:02:52.000Z\",\"publisher_count\":1,\"sources\":[\"CNBC\"],\"url\":\"https://www.cnbc.com/2026/11/18/hims-hers-peptides-plus-treatments.html\"},{\"statement\":\"Hims & Hers Health announced on Wednesday it will launch its Peptides+ platform offering five compounded peptide and longevity treatments manufactured in the United States.\",\"source\":\"CNBC\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-18T14:02:52.000Z\",\"publisher_count\":1,\"sources\":[\"CNBC\"],\"url\":\"https://www.cnbc.com/2026/11/18/hims-hers-peptides-plus-treatments.html\"},{\"statement\":\"None of the specific compounded peptide products offered by Hims & Hers have received approval from the United States Food and Drug Administration.\",\"source\":\"CNBC\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-18T14:02:52.000Z\",\"publisher_count\":1,\"sources\":[\"CNBC\"],\"url\":\"https://www.cnbc.com/2026/11/18/hims-hers-peptides-plus-treatments.html\"},{\"statement\":\"Morgan Stanley cut its target to $25 from $28 and kept an Equal-Weight rating.\",\"source\":\"Blockchain.News\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-17T23:54:20.000Z\",\"publisher_count\":1,\"sources\":[\"Blockchain.News\"],\"url\":\"https://blockchain.news/news/20261117-price-prediction-hims-analysts-trim-targets-as-the-chart\"},{\"statement\":\"Needham lowered its target to $32 from $42 while staying Buy.\",\"source\":\"Blockchain.News\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-17T23:54:20.000Z\",\"publisher_count\":1,\"sources\":[\"Blockchain.News\"],\"url\":\"https://blockchain.news/news/20261117-price-prediction-hims-analysts-trim-targets-as-the-chart\"},{\"statement\":\"Over 10,000 people signed up for Hims & Hers peptide treatment early access waitlist within 15 days of its launch in late October, per a company spokesperson.\",\"source\":\"CNBC\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-18T14:02:52.000Z\",\"publisher_count\":1,\"sources\":[\"CNBC\"],\"url\":\"https://www.cnbc.com/2026/11/18/hims-hers-peptides-plus-treatments.html\"},{\"statement\":\"Jefferies cut its target to $24 from $31 and kept Hold.\",\"source\":\"Blockchain.News\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-17T23:54:20.000Z\",\"publisher_count\":1,\"sources\":[\"Blockchain.News\"],\"url\":\"https://blockchain.news/news/20261117-price-prediction-hims-analysts-trim-targets-as-the-chart\"},{\"statement\":\"The stock is below its short-, medium-, and long-term moving averages.\",\"source\":\"Blockchain.News\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-11-17T23:54:20.000Z\",\"publisher_count\":1,\"sources\":[\"Blockchain.News\"],\"url\":\"https://blockchain.news/news/20261117-price-prediction-hims-analysts-trim-targets-as-the-chart\"}]",
    "kind": "news"
  },
  "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature",
  "receipt": {
    "slice_hash": "d6ae367ed09f41a5d2c15152324af3c53072651e72d7bb9d533b84a89318978d",
    "cursor_from": "ingest:raw_newsroomfloor.stories:d6ae367ed09f41a5",
    "cursor_to": "ingest:raw_newsroomfloor.stories:d6ae367ed09f41a5",
    "view": "ingest:raw_newsroomfloor.stories",
    "view_version": "1",
    "row_count": 1,
    "hash_basis": "sha256 over the JSON array of {insertId, json} rows as received (normalized wire shape), computed before the BigQuery forward",
    "credits": 0.01,
    "price_per_100_rows_written": 1,
    "sig": "7nAy5Z2VLjBENHPdBAGmbBcDDZoqHujlL5uZ4ihd8yTQomyZ4LsTn-WGJEA6MZDIjt6hgoleRr6jivlzUWg9BA",
    "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
    "signer_path": "lakehouse/data-extract/v1",
    "alg": "Ed25519",
    "signed": true
  },
  "receipt_note": "the ingest door's signed receipt for this revision, verbatim as the door returned it",
  "generation_chain": {
    "wire": {
      "stream": "fountain_news",
      "story_id": "4cf9681afb14263c0b194fca5c7f3b76",
      "thread_id": "17429bd219750d9f321d35d2a41f7381",
      "thread_label": "Hims & Hers Health",
      "novelty": "UPDATE",
      "content_hash": "f91fbd2793bf5be2983e6b1296b7976488f46fdd9dda513346fa26fb703bb53d",
      "compose": 3,
      "last_published_at": "2026-11-18T14:02:52.000Z",
      "read_receipt": {
        "slice_hash": "218f088f67fa000dc0fbc8fdd2ee6f1b5d0a34ad9721face19311fc3fcd41903",
        "cursor_from": "eyJ0cyI6IjIwMjYtMTEtMThUMTM6NDc6MDQuMDAwWiIsImlkIjoiYjJmNDc0Y2U5MGJmMzJiNzIwODA5MmRhZDIyMjk0OTUiLCJ2IjoiMSJ9",
        "cursor_to": "eyJ0cyI6IjIwMjYtMTEtMThUMTU6Mzg6MjYuMDAwMDAwWiIsImlkIjoiOWE2NTExNGNmMTBmYjg4M2ZhNzY0MTM4NmU0OWNkZGYiLCJ2IjoiMSJ9",
        "view": "v_fountain_news",
        "view_version": "1",
        "row_count": 100,
        "window_days": 3,
        "bytes_scanned": 3577351,
        "credits": 8,
        "price_per_100_rows": 8,
        "sig": "Lykaf-PhO6r60RvvINpmnX97V3_53aW_ShFps9QcEbcgHStCZsHb89sEwDBnD54eBhr4HNif-ZS45SvRRSrVBg",
        "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
        "signer_path": "lakehouse/data-extract/v1",
        "alg": "Ed25519",
        "signed": true
      },
      "landing": "air"
    },
    "written_at": "2026-11-19T21:22:48.406Z"
  },
  "cited_facts": [
    {
      "n": 1,
      "statement": "Hims & Hers chief medical officer Dr. Anant Vinjamoori stated that full clinical data on optimal use and efficacy of the offered peptides is not currently available.",
      "source": "CNBC",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.cnbc.com/2026/11/18/hims-hers-peptides-plus-treatments.html",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 2,
      "statement": "Hims & Hers Health announced on Wednesday it will launch its Peptides+ platform offering five compounded peptide and longevity treatments manufactured in the United States.",
      "source": "CNBC",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.cnbc.com/2026/11/18/hims-hers-peptides-plus-treatments.html",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 3,
      "statement": "None of the specific compounded peptide products offered by Hims & Hers have received approval from the United States Food and Drug Administration.",
      "source": "CNBC",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.cnbc.com/2026/11/18/hims-hers-peptides-plus-treatments.html",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 4,
      "statement": "Morgan Stanley cut its target to $25 from $28 and kept an Equal-Weight rating.",
      "source": "Blockchain.News",
      "instrument": "News",
      "claim_key": null,
      "url": "https://blockchain.news/news/20261117-price-prediction-hims-analysts-trim-targets-as-the-chart",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 5,
      "statement": "Needham lowered its target to $32 from $42 while staying Buy.",
      "source": "Blockchain.News",
      "instrument": "News",
      "claim_key": null,
      "url": "https://blockchain.news/news/20261117-price-prediction-hims-analysts-trim-targets-as-the-chart",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 6,
      "statement": "Over 10,000 people signed up for Hims & Hers peptide treatment early access waitlist within 15 days of its launch in late October, per a company spokesperson.",
      "source": "CNBC",
      "instrument": "News",
      "claim_key": null,
      "url": "https://www.cnbc.com/2026/11/18/hims-hers-peptides-plus-treatments.html",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 7,
      "statement": "Jefferies cut its target to $24 from $31 and kept Hold.",
      "source": "Blockchain.News",
      "instrument": "News",
      "claim_key": null,
      "url": "https://blockchain.news/news/20261117-price-prediction-hims-analysts-trim-targets-as-the-chart",
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 8,
      "statement": "The stock is below its short-, medium-, and long-term moving averages.",
      "source": "Blockchain.News",
      "instrument": "News",
      "claim_key": null,
      "url": "https://blockchain.news/news/20261117-price-prediction-hims-analysts-trim-targets-as-the-chart",
      "occurred_at": null,
      "published_at": null
    }
  ],
  "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true. The dates on cited_facts (occurred_at, published_at) are the forge's, joined at read time; they are not part of the signed basis above."
}